Clinical trial results:
A study to compare GW815SF HFA MDI with concomitant treatment with salmeterol xinafoate DPI plus fluticasone propionate DPI and to assess long-term safety of GW815SF HFA MDI.

Summary

EudraCT number	2015-004882-10
Trial protocol	Outside EU/EEA
Global end of trial date	19 January 2008

Results information

Result version number	v1 (current)
This version publication date	14 January 2017
First version publication date	14 January 2017

Trial information

Trial identification

Sponsor protocol code	110099

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 March 2008
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	19 January 2008
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

TBD

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 April 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Japan: 52
Worldwide total number of subjects	52
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	47
Adolescents (12-17 years)	5
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 51 participants were randomized to the crossover period, out of which 50 completed the extension period.

Period 1

Period 1 title	Overall study
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	SFC 50/100 mcg/day First

Arm description:

GW815SF (SFC; Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in first intervention period and SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in second intervention period (after washout period).

Arm type	Active comparator
Investigational medicinal product name	GW815SF (Salmeterol/Fluticasone propionate combination[SFC]) 25/50 microgram (mcg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

GW815SF (SLM) 25/50mcg twice daily via Metered dose inhaler (MDI).

Investigational medicinal product name	Fluticasone propionate (FP) 50mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

FP 50mcg twice daily via DPI

Investigational medicinal product name	Salmeterol (SLM) 25mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

SLM 25 mcg twice daily via Dry powder inhaler (DPI)

Arm title	SLM 50 mcg + FP 100 mcg/day First

Arm description:

SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in first intervention period and GW815SF (SFC; Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in second intervention period (after washout period).

Arm type	Active comparator

Investigational medicinal product name	GW815SF (Salmeterol/Fluticasone propionate combination[SFC]) 25/50 microgram (mcg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

GW815SF (SLM) 25/50mcg twice daily via Metered dose inhaler (MDI).

Investigational medicinal product name	Fluticasone propionate (FP) 50mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

FP 50mcg twice daily via DPI

Investigational medicinal product name	Salmeterol (SLM) 25mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

SLM 25 mcg twice daily via Dry powder inhaler (DPI)

Number of subjects in period 1[1]	SFC 50/100 mcg/day First	SLM 50 mcg + FP 100 mcg/day First
Started	26	25
Completed	25	25
Not completed	1	0
other	1	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: A total of 52 participants were enrolled and 51 participants were randomized.

Period 2

Period 2 title	Treatment Period I - 4 weeks
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	No
Arm title	SFC 50/100 mcg/day First

Arm description:

GW815SF (SFC; Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in first intervention period and SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in second intervention period (after washout period).

Arm type	Active comparator

Investigational medicinal product name	GW815SF (Salmeterol/Fluticasone propionate combination[SFC]) 25/50 microgram (mcg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

GW815SF (SLM) 25/50mcg twice daily via Metered dose inhaler (MDI).

Investigational medicinal product name	Salmeterol (SLM) 25mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

SLM 25 mcg twice daily via Dry powder inhaler (DPI)

Investigational medicinal product name	Fluticasone propionate (FP) 50mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

FP 50mcg twice daily via DPI

Arm title	SLM 50 mcg + FP 100 mcg/day First

Arm description:

SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in first intervention period and GW815SF (SFC; Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in second intervention period (after washout period).

Arm type	Active comparator
Investigational medicinal product name	GW815SF (Salmeterol/Fluticasone propionate combination[SFC]) 25/50 microgram (mcg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

GW815SF (SLM) 25/50mcg twice daily via Metered dose inhaler (MDI).

Investigational medicinal product name	Fluticasone propionate (FP) 50mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

FP 50mcg twice daily via DPI

Investigational medicinal product name	Salmeterol (SLM) 25mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

SLM 25 mcg twice daily via Dry powder inhaler (DPI)

Number of subjects in period 2	SFC 50/100 mcg/day First	SLM 50 mcg + FP 100 mcg/day First
Started	26	25
Completed	26	25

Period 3	
Period 3 title	Washout Period-2 weeks
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	SFC 50/100 mcg/day First

Arm description:

GW815SF (SFC; Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in first intervention period and SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in second intervention period (after washout period).

Arm type	Active comparator
Investigational medicinal product name	GW815SF (Salmeterol/Fluticasone propionate combination[SFC]) 25/50 microgram (mcg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

GW815SF (SLM) 25/50mcg twice daily via Metered dose inhaler (MDI).

Investigational medicinal product name	Fluticasone propionate (FP) 50mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

FP 50mcg twice daily via DPI

Investigational medicinal product name	Salmeterol (SLM) 25mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

SLM 25 mcg twice daily via Dry powder inhaler (DPI)

Arm title	SLM 50 mcg + FP 100 mcg/day First

Arm description:	
SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in first intervention period and GW815SF (SFC; Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in second intervention period (after washout period).	
Arm type	Active comparator
Investigational medicinal product name	GW815SF (Salmeterol/Fluticasone propionate combination[SFC]) 25/50 microgram (mcg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use
Dosage and administration details:	
GW815SF (SLM) 25/50mcg twice daily via Metered dose inhaler (MDI).	
Investigational medicinal product name	Fluticasone propionate (FP) 50mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use
Dosage and administration details:	
FP 50mcg twice daily via DPI	
Investigational medicinal product name	Salmeterol (SLM) 25mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use
Dosage and administration details:	
SLM 25 mcg twice daily via Dry powder inhaler (DPI)	

Number of subjects in period 3	SFC 50/100 mcg/day First	SLM 50 mcg + FP 100 mcg/day First
Started	26	25
Completed	25	25
Not completed	1	0
WITHDRAWAL BY SUBJECT	1	-

Period 4	
Period 4 title	Treatment Period II - 4 weeks
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded
Arms	
Are arms mutually exclusive?	No

Arm title	SFC 50/100 mcg/day First

Arm description:

GW815SF (SFC; Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in first intervention period and SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in second intervention period (after washout period).

Arm type	Active comparator
Investigational medicinal product name	GW815SF (Salmeterol/Fluticasone propionate combination[SFC]) 25/50 microgram (mcg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

GW815SF (SLM) 25/50mcg twice daily via Metered dose inhaler (MDI).

Investigational medicinal product name	Fluticasone propionate (FP) 50mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

FP 50mcg twice daily via DPI

Investigational medicinal product name	Salmeterol (SLM) 25mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

SLM 25 mcg twice daily via Dry powder inhaler (DPI)

Arm title	SLM 50 mcg + FP 100 mcg/day First

Arm description:

SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in first intervention period and GW815SF (SFC; Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in second intervention period (after washout period).

Arm type	Active comparator
Investigational medicinal product name	GW815SF (Salmeterol/Fluticasone propionate combination[SFC]) 25/50 microgram (mcg)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

GW815SF (SLM) 25/50mcg twice daily via Metered dose inhaler (MDI).

Investigational medicinal product name	Fluticasone propionate (FP) 50mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

FP 50mcg twice daily via DPI

Investigational medicinal product name	Salmeterol (SLM) 25mcg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Inhalation powder
Routes of administration	Inhalation use

Dosage and administration details:

SLM 25 mcg twice daily via Dry powder inhaler (DPI)

Number of subjects in period 4	SFC 50/100 mcg/day First	SLM 50 mcg + FP 100 mcg/day First
Started	25	25
Completed	25	25

Baseline characteristics

Reporting groups	
Reporting group title	Overall study
Reporting group description:	
Overall study	

Reporting group values	Overall study	Total	
Number of subjects	51	51	
Age categorical Units: Subjects			
Age continuous			
Age continuous description			
Units: years			
arithmetic mean	8.3		
standard deviation	± 2.41	-	
Gender categorical			
Gender categorical description			
Units: Subjects			
Female	17	17	
Male	34	34	
Race/Ethnicity, Customized Units: Subjects			
Asian-Japanese Heritage	51	51	
Region of Enrollment Units: Subjects			
Japan	51	51	

End points

End points reporting groups

Reporting group title	SFC 50/100 mcg/day First

Reporting group description:

GW815SF (SFC; Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in first intervention period and SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in second intervention period (after washout period).

Reporting group title	SLM 50 mcg + FP 100 mcg/day First

Reporting group description:

SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in first intervention period and GW815SF (SFC; Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in second intervention period (after washout period).

Reporting group title	SFC 50/100 mcg/day First

Reporting group description:

GW815SF (SFC; Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in first intervention period and SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in second intervention period (after washout period).

Reporting group title	SLM 50 mcg + FP 100 mcg/day First

Reporting group description:

SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in first intervention period and GW815SF (SFC; Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in second intervention period (after washout period).

Reporting group title	SFC 50/100 mcg/day First

Reporting group description:

GW815SF (SFC; Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in first intervention period and SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in second intervention period (after washout period).

Reporting group title	SLM 50 mcg + FP 100 mcg/day First

Reporting group description:

SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in first intervention period and GW815SF (SFC; Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in second intervention period (after washout period).

Reporting group title	SFC 50/100 mcg/day First

Reporting group description:

GW815SF (SFC; Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in first intervention period and SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in second intervention period (after washout period).

Reporting group title	SLM 50 mcg + FP 100 mcg/day First

Reporting group description:

SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in first intervention period and GW815SF (SFC; Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in second intervention period (after washout period).

Subject analysis set title	SFC 50/100mcg/day
Subject analysis set type	Per protocol

Subject analysis set description:

Per Protocol Set who received GW815SF (SFC , Salmeterol/Fluticasone propionate combination) HFA (HydroFluoroAlkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily

Subject analysis set title	SLM 50mcg + FP 100mcg/day
Subject analysis set type	Per protocol

Subject analysis set description:

Per Protocol Set who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily

Subject analysis set title	SFC 50/100 MCG/DAY
Subject analysis set type	Full analysis

Subject analysis set description:

Full Analysis Set who received GW815SF (SFC , Salmeterol/Fluticasone propionate combination) HFA (HydroFluoroAlkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily

Primary: Adjusted Mean Change from Baseline in Morning PEF (Peak Expiratory Flow) during the 4-week Treatment Periods

End point title	Adjusted Mean Change from Baseline in Morning PEF (Peak Expiratory Flow) during the 4-week Treatment Periods

End point description:

Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out (i.e., the last 7 days prior to the day of starting treatment period [Weeks 1-4/Weeks 7-10]).

End point type	Primary

End point timeframe:

Crossover Period Weeks 1-4, and 7-10

End point values	SFC 50/100mcg/day	SLM 50mcg + FP 100mcg/day		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	48[1]	48[2]		
Units: Liters/minute				
arithmetic mean (standard error)	14.3 (± 4.53)	17.1 (± 4.53)		

Notes:

[1] - PPS (Per Protocol Set): randomized subjects less those who did not complete treatment.

[2] - PPS (Per Protocol Set): randomized subjects less those who did not complete treatment.

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Difference between treatments [(SLM + FP)- SFC](SE) 2.8 (5.91)

Comparison groups	SFC 50/100mcg/day v SLM 50mcg + FP 100mcg/day
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	equivalence[3]
P-value	= 0.6383 [4]
Method	Mixed models analysis
Parameter estimate	Mean difference (net)
Point estimate	2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.1
upper limit	14.69

Variability estimate	Standard error of the mean
Dispersion value	5.91

Notes:

[3] - Equivalence margin + or - 15 L/min

[4] - Confidence Interval

Secondary: Adjusted Mean Change from Baseline in Percent Predicted Morning PEF(%) during the 4-week Treatment Periods

End point title	Adjusted Mean Change from Baseline in Percent Predicted Morning PEF(%) during the 4-week Treatment Periods

End point description:

Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.

End point type	Secondary

End point timeframe:

Crossover Period Weeks 1-4, 7-10

End point values	SFC 50/100mcg/day	SLM 50mcg + FP 100mcg/day		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	48[5]	48[6]		
Units: Percentage of predicted value				
arithmetic mean (standard error)	5.38 (± 1.543)	6.73 (± 1.543)		

Notes:

[5] - PPS

[6] - PPS

Statistical analyses

No statistical analyses for this end point

Secondary: Adjusted Mean Change from Baseline in Percent Personal Best Morning PEF(%) during the 4-week Treatment Periods

End point title	Adjusted Mean Change from Baseline in Percent Personal Best Morning PEF(%) during the 4-week Treatment Periods

End point description:

Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.

End point type	Secondary

End point timeframe:

Crossover Period weeks 1-4, 7-10

End point values	SFC 50/100mcg/day	SLM 50mcg + FP 100mcg/day		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	48[7]	48[8]		
Units: Percentage of personal best value				
arithmetic mean (standard error)	5.01 (± 1.48)	6.46 (± 1.48)		

Notes:

[7] - PPS

[8] - PPS

Statistical analyses

No statistical analyses for this end point

Secondary: Adjusted Mean Change from Baseline in Evening PEF during the 4-week Treatment Periods

End point title	Adjusted Mean Change from Baseline in Evening PEF during the 4-week Treatment Periods

End point description:

Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.

End point type	Secondary

End point timeframe:

Crossover Period weeks 1-4, 7-10

End point values	SFC 50/100mcg/day	SLM 50mcg + FP 100mcg/day		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	48[9]	48[10]		
Units: L/min				
arithmetic mean (standard error)	16.3 (± 3.74)	15.8 (± 3.74)		

Notes:

[9] - PPS

[10] - PPS

Statistical analyses

No statistical analyses for this end point

Secondary: Adjusted Mean Change from Baseline of Circadian Variation in Morning PEF(%) during the 4-week Treatment Periods

End point title	Adjusted Mean Change from Baseline of Circadian Variation in Morning PEF(%) during the 4-week Treatment Periods

End point description:

Mean change from baseline = value at each assessment period (mean of the values obtained at each assessment period [Weeks 1-4/Weeks 7-10]) minus baseline value. Baseline: Mean of the daily values over the last 7 days of the 2-week run-in/wash-out.

End point type	Secondary

End point timeframe:

Crossover Period Weeks 1-4, 7-10

End point values	SFC 50/100mcg/day	SLM 50mcg + FP 100mcg/day		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	48[11]	48[12]		
Units: Percentage of circadian variation				
arithmetic mean (standard error)	0.06 (± 0.638)	-0.08 (± 0.638)		

Notes:

[11] - PPS

[12] - PPS

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Symptom-Free Nights & Days

End point title	Percentage of Subjects with Symptom-Free Nights & Days

End point description:

Percentage of subjects with Symptom Free Nights & Days after 4 weeks of Treatment

End point type	Secondary

End point timeframe:

Crossover Period Week 1-4, 7-10

End point values	SFC 50/100mcg/day	SLM 50mcg + FP 100mcg/day		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	48[13]	48[14]		
Units: Percent of participants				
number (not applicable)				
Baseline	72.9	81.3		
After 4 Weeks of Treatment	91.7	81.3		

Notes:

[13] - PPS

[14] - PPS

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Rescue Medication-Free Nights and Days

End point title	Percentage of Subjects with Rescue Medication-Free Nights and Days

End point description:

Percentage of subjects with Rescue Medication Free Nights & Days after 4 weeks of Treatment

End point type	Secondary

End point timeframe:

Crossover Period Weeks 1-4, 7-10

End point values	SFC 50/100mcg/day	SLM 50mcg + FP 100mcg/day		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	48[15]	48[16]		
Units: Percentage of participants				
number (not applicable)				
Baseline	87.5	87.5		
After 4 Weeks of Treatment	93.8	87.5		

Notes:

[15] - PPS

[16] - PPS

Statistical analyses

No statistical analyses for this end point

Secondary: Adjusted Mean Change from Baseline in Morning PEF during the 20-week Extension Treatment Period

End point title	Adjusted Mean Change from Baseline in Morning PEF during the 20-week Extension Treatment Period

End point description:

Mean change from baseline = value at assessment period (mean of the values obtained at assessment period (Weeks 11-30).) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting of the Extension period (Weeks 11-30).

FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.

End point type	Secondary

End point timeframe:

Extension Period Weeks 11-30

End point values	SFC 50/100 MCG/DAY			
Subject group type	Subject analysis set			
Number of subjects analysed	50[17]			
Units: L/min				
arithmetic mean (standard deviation)	3 (± 24.56)			

Notes:

[17] - FAS

Statistical analyses

No statistical analyses for this end point

Secondary: Adjusted Mean Change from Baseline in Percent Predicted Morning PEF(%) during the 20-Week Extension Treatment Period

End point title	Adjusted Mean Change from Baseline in Percent Predicted Morning PEF(%) during the 20-Week Extension Treatment Period

End point description:

Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).

FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.

End point type	Secondary

End point timeframe:

Extension Period weeks 11-30

End point values	SFC 50/100 MCG/DAY			
Subject group type	Subject analysis set			
Number of subjects analysed	50[18]			
Units: Percentage of predicted value				
arithmetic mean (standard deviation)	1.46 (± 9.568)			

Notes:

[18] - FAS

Statistical analyses

No statistical analyses for this end point

Secondary: Adjusted Mean Change from Baseline in Percent Personal Best Morning PEF(%) during the 20-week Extension Treatment Period

End point title	Adjusted Mean Change from Baseline in Percent Personal Best Morning PEF(%) during the 20-week Extension Treatment Period

End point description:

Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).

FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.

End point type	Secondary

End point timeframe:

Extension Period weeks 11-30

End point values	SFC 50/100 MCG/DAY			
Subject group type	Subject analysis set			
Number of subjects analysed	50[19]			
Units: Percentage of personal best value				
arithmetic mean (standard deviation)	1.29 (± 8.541)			

Notes:

[19] - FAS

Statistical analyses

No statistical analyses for this end point

Secondary: Adjusted Mean Change from Baseline of Circadian Variation in PEF(%) during the 20-Week Extension Treatment Period

End point title	Adjusted Mean Change from Baseline of Circadian Variation in PEF(%) during the 20-Week Extension Treatment Period

End point description:

Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).

FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.

End point type	Secondary

End point timeframe:

Extension Period weeks 11-30

End point values	SFC 50/100 MCG/DAY			
Subject group type	Subject analysis set			
Number of subjects analysed	50[20]			
Units: Percentage of circadian variation				
arithmetic mean (standard deviation)	2.7 (± 23.43)			

Notes:

[20] - FAS

Statistical analyses

No statistical analyses for this end point

Secondary: Adjusted Mean Change from Baseline in Evening PEF during the 20-week Extension Treatment Period

End point title	Adjusted Mean Change from Baseline in Evening PEF during the 20-week Extension Treatment Period

End point description:

Mean change from baseline = value at assessment period (mean of the values obtained at assessment period [Weeks 11-30]) minus baseline value. Baseline: Mean of the daily values over the last 7 days prior to the day of starting the Extension period (Weeks 11-30).

FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.

End point type	Secondary

End point timeframe:

Extension Period weeks 11-30

End point values	SFC 50/100 MCG/DAY			
Subject group type	Subject analysis set			
Number of subjects analysed	50[21]			
Units: L/Min				
arithmetic mean (standard deviation)	-0.37 (± 3.568)			

Notes:

[21] - FAS

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Symptom-Free Nights & Days after 20 Weeks of Treatment

End point title	Percentage of Subjects with Symptom-Free Nights & Days after 20 Weeks of Treatment

End point description:

Percentage of subjects with Symptom Free Nights & Days after 20 weeks of Treatment (at week 30).

FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.

End point type	Secondary

End point timeframe:

Extension Period Weeks 11-30

End point values	SFC 50/100 MCG/DAY			
Subject group type	Subject analysis set			
Number of subjects analysed	50[22]			
Units: Percentage of participants				
number (not applicable)				
Baseline After 20 weeks of treatment (at week 30)	84 84.8			

Notes:

[22] - FAS

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Rescue Medication-Free Nights & Days after

20 Weeks of Treatment

End point title	Percentage of Subjects with Rescue Medication-Free Nights & Days after 20 Weeks of Treatment

End point description:

Percentage of subjects with Rescue Medication Free Nights & Days after 20 weeks of Treatment (at week 30).

FAS (Full Analysis Set) during the Extension period: all subjects switched to Extension period and received GW815SF HFA MDI.

End point type	Secondary

End point timeframe:

Extension Period Weeks 11-30

End point values	SFC 50/100 MCG/DAY			
Subject group type	Subject analysis set			
Number of subjects analysed	50[23]			
Units: Percentage of participants				
number (not applicable)				
Baseline	90			
After 20 weeks of treatment (at week 30)	89.1			

Notes:

[23] - FAS

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
From Baseline to Week 32	
Assessment type	Systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	10

Reporting groups	
Reporting group title	SFC 50/100 mcg/day
Reporting group description:	
Safety Population who received GW815SF (SFC, Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in Crossover Period Weeks 1-4 and 7-10	
Reporting group title	SFC 50/100mcg/day (Extension Period)
Reporting group description:	
Safety Population who switched to Extension Period and received GW815SF HFA MDI 25/50mcg twice daily during the Extension period	
Reporting group title	SLM 50 + FP 100 mcg/day
Reporting group description:	
Safety Population who received SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg +FP (Fluticasone Propionate) DPI 50 mcg twice daily in Crossover Period Weeks 1-4 and 7-10	

Serious adverse events	SFC 50/100 mcg/day	SFC 50/100mcg/day (Extension Period)	SLM 50 + FP 100 mcg/day
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 51 (0.00%)	0 / 50 (0.00%)	0 / 50 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	SFC 50/100 mcg/day	SFC 50/100mcg/day (Extension Period)	SLM 50 + FP 100 mcg/day
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 51 (17.65%)	35 / 50 (70.00%)	7 / 50 (14.00%)
Gastrointestinal disorders			
Stomatitis			
alternative dictionary used: MedDRA 10			
subjects affected / exposed	0 / 51 (0.00%)	3 / 50 (6.00%)	0 / 50 (0.00%)
occurrences (all)	0	4	0
Respiratory, thoracic and mediastinal			

disorders			
Upper Respiratory Tract inflammation			
alternative dictionary used: MedDRA 10			
subjects affected / exposed	7 / 51 (13.73%)	17 / 50 (34.00%)	3 / 50 (6.00%)
occurrences (all)	10	30	4
Asthma			
alternative dictionary used: MedDRA 10			
subjects affected / exposed	0 / 51 (0.00%)	5 / 50 (10.00%)	0 / 50 (0.00%)
occurrences (all)	0	8	0
Skin and subcutaneous tissue disorders			
Eczema			
alternative dictionary used: MedDRA 10			
subjects affected / exposed	0 / 51 (0.00%)	4 / 50 (8.00%)	0 / 50 (0.00%)
occurrences (all)	0	4	0
Infections and infestations			
Nasopharyngitis			
alternative dictionary used: MedDRA 10.0			
subjects affected / exposed	2 / 51 (3.92%)	7 / 50 (14.00%)	4 / 50 (8.00%)
occurrences (all)	2	10	4
Gastroenteritis			
alternative dictionary used: MedDRA 10			
subjects affected / exposed	0 / 51 (0.00%)	7 / 50 (14.00%)	0 / 50 (0.00%)
occurrences (all)	0	8	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported